Rational therapeutic targeting of myeloid cells in glioblastoma: challenges and perspectives

Akay, Faruk et Saleh, Maya ORCID: https://orcid.org/0000-0003-1538-9146 (2025). Rational therapeutic targeting of myeloid cells in glioblastoma: challenges and perspectives Frontiers in Immunology , vol. 16 , nº 1472710. pp. 1-16. DOI: 10.3389/fimmu.2025.1472710.

Prévisualisation

PDF - Version publiée Disponible sous licence Creative Commons Attribution. Télécharger (4MB) | Prévisualisation

Résumé

Glioblastoma (GB) is the most aggressive tumor of the central nervous system (CNS), accounting for almost 80% of all primary brain tumors. Despite standard-of-care consisting of surgical resection, when possible, adjuvant radiotherapy (RT) and chemotherapy with Temozolomide (TMZ), GB remains highly fatal, with an estimated recurrence rate of over 90% and a median overall survival (OS) of around 15 months from diagnosis. Several factors contribute to such poor patient outcome, including a unique myeloid-rich tumor microenvironment (TME) that confers immunosuppression and therapeutic resistance. Multi-omics, single-cell transcriptomics and multi-modal spatial analyses of GB are unraveling the diversity of brain myeloid cells, including activated microglia, border-associated macrophages (BAM), and monocyte-derived glioma-associated macrophages (GAM), instructed by ontogeny, spatial distribution, cell-cell interactions and response to metabolic cues in the TME. In this review, we elaborate on the heterogeneity and plasticity of myeloid cells in GB and discuss the promise and challenges for rational therapeutic targeting of GAMs in GB.

Type de document:	Article
Informations complémentaires:	Research on glioblastoma in Dr. Saleh's laboratory is supported by INRS, the Canadian Institutes of Health Research - CIHR # PJT-198052, the Natural Sciences and Engineering Research Council of Canada - NSERC # RGPIN-2025- 07017 and the Canada Foundation for Innovation - CFI # 44880
Mots-clés libres:	Central nervous system; clinical trials; glioblastoma; glioma-associated macrophages; immunotherapy; innate immunity; myeloid cells; tumor microenvironment
Centre:	Centre INRS-Institut Armand Frappier
Date de dépôt:	12 févr. 2026 16:12
Dernière modification:	12 févr. 2026 16:12
URI:	https://espace.inrs.ca/id/eprint/16584

Gestion Actions (Identification requise)

Modifier la notice